Glenmark Pharmaceuticals Ltd.
NSE: GLENMARK · Healthcare
Sector
Healthcare
Size band
Mid cap
Market cap
59,639cr
P/E
2,858.6
ROE
6.8%
Dividend yield
0.1%
No price is shown on this page, live or delayed. It records what management said on the earnings call, and the company’s filings.
Measured against
Peer set
Pharmaceuticals & Drugs · largest 12 of 82 measured at Q1 FY27 · financials via Screener| Company | Operating margin | Revenue growth |
|---|---|---|
| Sun Pharmaceutical Industries Ltd. | 29.0% | 10.5% |
| Divi's Laboratories Ltd. | 41.0% | 27.8% |
| Torrent Pharmaceuticals Ltd. | 34.0% | 54.8% |
| Lupin Ltd. | 30.0% | 32.1% |
| Dr. Reddy's Laboratories Ltd. | 11.0% | −5.5% |
| Cipla Ltd. | 17.0% | 2.3% |
| Zydus Lifesciences Ltd. | 24.0% | 22.0% |
| Mankind Pharma Ltd. | 26.0% | 12.9% |
| Aurobindo Pharma Ltd. | 21.0% | 16.3% |
| Torrent Power Ltd. | 19.0% | 2.8% |
| Alkem Laboratories Ltd. | 20.0% | 10.9% |
| Glenmark Pharmaceuticals Ltd. | 20.0% | 23.1% |
No guidance on record.
This section quotes what management told the market on the quarterly earnings call. We have not transcribed one for Glenmark Pharmaceuticals Ltd..
On air
20 calls · outcomes not trackedRecorded as stated on air, with the analyst's SEBI registration status where it was given. Anchor calls carry no registration and are marked. Bharatstox does not make, endorse or repeat these calls, and none of them is our view.
| Channel & show | Aired | Stated target | Stated stop | Outcome |
|---|---|---|---|---|
| CNBC AwaazCNBC Awaax · no registration attached | 9 Oct | +3.1% | -1.3% | still open |
| Zee BusinessZee Business · no registration attached | 7 Oct | +12.2% | — | still open |
| Zee BusinessZee Business · no registration attached | 7 Oct | +13.6% | — | still open |
| CNBC AwaazCNBC Awaax · no registration attached | 23 Sep | +2.7% | -1.2% | still open |
| CNBC AwaazCNBC Awaax · no registration attached | 8 Sep | +2.1% | -0.9% | still open |
| CNBC AwaazCNBC Awaax · no registration attached | 8 Sep | +2.0% | -1.0% | still open |
| Zee BusinessZee Business · no registration attached | 8 Sep | +2.3% | -1.1% | still open |
| Zee BusinessZee Business · no registration attached | 8 Sep | +2.3% | — | still open |
| Zee BusinessZee Business · no registration attached | 8 Sep | +5.6% | — | still open |
| Zee BusinessZee Business · no registration attached | 8 Sep | +2.0% | -2.1% | still open |
| Zee BusinessZee Business · no registration attached | 8 Sep | +3.2% | -2.1% | still open |
| Zee BusinessZee Business · no registration attached | 8 Sep | +2.4% | -1.1% | still open |
| CNBC AwaazCNBC Awaax · no registration attached | 7 Sep | +2.4% | -0.9% | still open |
| CNBC AwaazCNBC Awaax · no registration attached | 7 Sep | +1.6% | -0.9% | still open |
| CNBC AwaazCNBC Awaax · no registration attached | 27 Aug | +3.8% | -1.8% | still open |
| CNBC AwaazCNBC Awaax · no registration attached | 27 Aug | +1.8% | -1.8% | still open |
| CNBC AwaazCNBC Awaax · no registration attached | 27 Aug | +3.8% | -1.9% | still open |
| CNBC AwaazCNBC Awaax · no registration attached | 27 Aug | +1.8% | -1.9% | still open |
| CNBC AwaazCNBC Awaax · no registration attached | 27 Aug | +0.8% | -1.7% | still open |
| CNBC AwaazCNBC Awaax · no registration attached | 26 Aug | +2.7% | -1.0% | still open |
Shareholding
change across 4 filings| Category | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Change |
|---|---|---|---|---|---|
| Promoters | 46.7 | 46.7 | 46.7 | 46.7 | 0.0 |
| Foreign institutions | 20.9 | 20.3 | 19.2 | 20.7 | +0.2 |
| Domestic institutions | 18.6 | 19.3 | 20.1 | 18.6 | 0.0 |
| Retail & others | 13.9 | 13.7 | 14.1 | 14.0 | −0.1 |
As filed with the exchange for the periods ending Sep 25 to Jun 26.
Filings
latest 25 of 272- Press Release6 Oct 2026
- Trading Window28 Sept 2026
- Glenmark Pharmaceuticals receives Establishment Inspection Report (EIS) from U.S. FDA for its Goa facility with VAI classification23 Sept 2026
- Press Release23 Sept 2026
- Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Schedule of Analyst/ Institutional Investor Meetings21 Sept 2026
- Analysts/Institutional Investor Meet/Con. Call Updates21 Sept 2026
- Report of Scrutinizer is enclosed11 Sept 2026
- Proceedings of the 48th AGM of the Company is enclosed11 Sept 2026
- Shareholders meeting11 Sept 2026
- Press Release11 Sept 2026
- Glenmark expands Global Respiratory Innovation Footprint with RYALTRIS launch in Brazil11 Sept 2026
- Please find enclosed rating rationale issued by India Ratings and Research11 Sept 2026
- Credit Rating11 Sept 2026
- Press Release21 Aug 2026
- Press Release20 Aug 2026
- General Updates13 Aug 2026
- Shareholders meeting13 Aug 2026
- Settlement Agreement - Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 201511 Aug 2026
- General Updates11 Aug 2026
- Options to purchase securities10 Aug 2026
- Analysts/Institutional Investor Meet/Con. Call Updates7 Aug 2026
- Copy of Newspaper Publication7 Aug 2026
- Analysts/Institutional Investor Meet/Con. Call Updates5 Aug 2026
- Analysts/Institutional Investor Meet/Con. Call Updates3 Aug 2026
- Updates31 Jul 2026
The 25 most recent of 272 filings we hold for GLENMARK, back to January 2024. Every filing, by day.
Disclaimer
Guidance is quoted from management commentary on quarterly earnings calls; the words are the company's own and the targets are theirs, not ours. Peer comparisons use quarterly financials sourced from Screener, with every company measured at the same fiscal quarter; the peer set is companies sharing the same industry classification, and comparisons are descriptive, not a ranking or a view. Broadcast calls are reproduced as stated on air, attributed, with the analyst's SEBI registration status where given; they are not our calls and not our view. Filings are reproduced as companies filed them to the NSE and BSE; Bharatstox does not verify, endorse or comment on their contents. This page is for informational and educational purposes only and does not constitute investment advice, research, or a recommendation to buy or sell any security. Investing in securities markets is subject to market risks. Read all related documents carefully before investing.